跳至主要内容
临床试验/NCT07078942
NCT07078942尚未招募4 期

Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section : A Randomized Controlled Trial

Chulalongkorn University1 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2025年7月20日最近更新:
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
入组人数
98
试验地点
1
主要终点
Blood loss

研究概览

简要总结

The purpose of this study is to asses the effect of preoperative prophylactic intravenous tranexamic acid on perioperative blood loss in pregnant women undergoing cesarean section

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • pregnant women with gestational age 37-42 weeks
  • undergoing cesarean delivery with indication as follows: placenta previa, severe preeclampsia, myoma uteri, fetal macrosomia, polyhydramnios, grand multiparity ≥ 5 deliveries, prolonged labor, etc.

排除标准

  • history of allergy to tranexamic acid
  • history of venous thromboembolism (Deep vein thrombosis, Pulmonary embolism)
  • history of arterial thrombosis (Myocardial infarction, Stroke)
  • history of seizure, convulsion
  • have underlying of cardiovascular, renal or liver disease
  • using of antiplatelet or anticoagulant within 1 week before operation
  • placenta accreta spectrum
  • abruptio placenta
  • Eclampsia or HELLP (Hemolysis Elevated Liver Low Platelet) syndrome
  • Failed operative vaginal delivery
  • Multifetal gestation

研究组 & 干预措施

Tranexamic acid

Active Comparator

Tranexamic acid (1 g) 20 ml intravenous preoperation

干预措施: Tranexamic Acid (Drug)

Placebo

Placebo Comparator

Normal saline 20 ml intravenous preoperation

干预措施: Placebo (Other)

结局指标

主要结局

Blood loss

时间窗: From enrollment to the end of operation

blood loss in ml

次要结局

  • early postpartum hemorrhage(From starting operation to 24-hour postoperation)
  • delayed postpartum hemorrhage(From starting operation to 6 weeks postpartum)
  • Adverse effects(from enrollment to 6 weeks postpartum)
  • Neonatal outcomes(from starting operation to 10 minutes after birth)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vorapong Phupong

Professor

Chulalongkorn University

研究点 (1)

Loading locations...

相似试验